丙肝的治疗策略药物的选择.pptVIP

派罗欣HCV Global Slide Kit 派罗欣HCV Global Slide Kit Slide *. PEGASYS? maintains consistent plasma levels over a week PEGASYS? is associated with antiviral coverage that is sustained throughout the weekly dosing interval. After one subcutaneous injection of PEGASYS? 180 μg, the serum drug level reaches a maximum concentration of 14.2 ng/mL (bottom curve).1 Unlike the drug concentration-time curve for unpegylated interferons2, serum concentrations of PEGASYS? are constant and sustained throughout the week. Until steady state is reached (5 to 9 weeks), serum concentrations more than double and are constant and sustained throughout the week.3 After steady state is reached, further drug accumulation does not occur (the amount of PEGASYS? eliminated from the body equals the amount entering via administration). The concentration-time curve for the week 9 injection (not shown) would be similar to that for the week 48 injection (top curve).3 Once the entire treatment course with PEGASYS? 180 μg once weekly has been completed, the serum concentration levels slowly descend; complete elimination of the drug occurs within 50 to 60 days post-treatment.3 1. Algranati N, et al. Hepatology 1999; 30(Suppl 2): 190A 2. Koslowski A, et al. BioDrugs 2001; 15: 419 3. Modi M, et al. Hepatology 2000; 32(Suppl): 394 派罗欣HCV Global Slide Kit Slide *. PEGASYS? plus VX-950 leads to rapid viral load decline without viral rebound In contrast to results seen with pegylated interferon alfa-2b (12KD) and new molecules for the treatment of hepatitis C, PEGASYS? has been associated with consistent and substantial viral load decline, consistent with sustained serum concentrations over the entire once-weekly dosing interval. VX-950 is a highly selective peptidomimetic inhibitor of the HCV NS3-4A protease that is designed to stop virus replication with a shorter treatment duration than current pegylated interferons. VX-950 monotherapy has been shown to have substantial antiviral effects which are incr